Stockscreener 앱 받기
47.50
247.73%
33.84
시장 영업 전:
50.10
2.60
+5.47%
전일 마감가:
$13.66
열려 있는:
$39.36
하루 거래량:
69.72M
Relative Volume:
31.99
시가총액:
$2.61B
수익:
$14.34M
순이익/손실:
$-199.00M
주가수익비율:
-12.12
EPS:
-3.92
순현금흐름:
$-183.51M
1주 성능:
+235.45%
1개월 성능:
+202.55%
6개월 성능:
+221.60%
1년 성능:
+824.12%
1일 변동 폭
$37.12
$51.21
1주일 범위
$13.65
$51.21
52주 변동 폭
$4.45
$51.21
Uniqure N V Stock (QURE) Company Profile
명칭
Uniqure N V
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
QURE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
47.50 | 749.48M | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-14 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure N V 주식(QURE)의 최신 뉴스
UniQure’s stocks up after AMT-130 trial win - European Biotechnology Magazine
BABA, INTC, QURE, TSLA, OPEN: 5 Trending Stocks TodayAlibaba Gr Hldgs (NYSE:BABA), Intel (NASDAQ:INTC) - Benzinga
Top Stocks today: uniQure, Lithium Americas and Tesla soar - Yahoo Finance
uniQure launches $200 million public offering of ordinary shares By Investing.com - Investing.com Australia
uniQure stock soars after positive Huntington’s disease drug results - Investing.com
uniQure (QURE) Stock: Soars 247% on $200 Million Public Offering Plan - parameter.io
uniQure (QURE) Analyst Raises Price Target to $68 With Outperform Rating | QURE Stock News - GuruFocus
UniQure Stock Soars: Too Late to Buy? - timothysykes.com
Top stocks today: Tesla, uniQure, and Lithium Americas soar - TheStreet
uniQure (QURE) Launches $200M Public Offering, Sees After-Hours Stock Surge - GuruFocus
Experimental gene therapy found to slow Huntington’s disease progression, company says - CNN
UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’ - Stocktwits
uniQure launches $200 million public offering of ordinary shares - Investing.com
Uniqure stock soars over 247% today after breakthrough Huntington’s disease drug results - The Economic Times
UniQure launches $200 mln equity offering after shares skyrocket - TradingView
uniQure (QURE) Initiates $200 Million Public Offering - GuruFocus
uniQure announces $200 million proposed public offering - MSN
uniQure announces $200M ordinary shares offering - TipRanks
Here’s why biotech UniQure’s stock just tripled, and brought ClearPoint shares up with it - MarketWatch
UniQure Huntington’s Gene Therapy Launch Planning Underway - insights.citeline.com
uniQure Announces $200 Million Proposed Public Offering - The Manila Times
uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond (QURE) - Seeking Alpha
Hunting down Huntington’s: Uniqure’s pivotal win - BioWorld MedTech
UniQure Celebrates A Groundbreaking Moment For Huntington’s Disease - insights.citeline.com
$200 Million Share Offering: Gene Therapy Leader uniQure Seeks Capital for Transformative Therapies - Stock Titan
Promising Medical Stocks To Watch TodaySeptember 24th - MarketBeat
Stifel Raises Price Target for uniQure (QURE) to 65.00 USD | QUR - GuruFocus
uniQure (NASDAQ:QURE) Given New $65.00 Price Target at Stifel Nicolaus - MarketBeat
Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph - ts2.tech
This Stock Is Tripling on a Key Gene Therapy Win. Should You Buy the 200%-Plus Surge Now? - inkl
uniQure (QURE) Analyst Raises Price Target to $68 With Outperfor - GuruFocus
uniQure (NASDAQ:QURE) Given New $68.00 Price Target at Leerink Partners - MarketBeat
uniQure stock price target raised to $68 from $48 at Leerink Partners - Investing.com Canada
What's Going On With UniQure Stock Wednesday? - Benzinga
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today - MSN
UniQure's Shares Soar After Phase 1/2 Trial in Huntington's Disease Meets Primary Endpoint - MarketScreener
uniQure Stock Doubles On Promising Data From Huntington's Disease Trial - AOL.com
First Successful Gene Therapy for Huntington's Disease Slows Disease Progression by 75% - inkl
A Cure For Huntington's Disease? UniQure Launches Nearly 250%. - inkl
uniQure (QURE) Sees Positive Results in Huntington's Disease Trials - GuruFocus
uniQure (QURE) Receives Consistent Buy Rating from HC Wainwright & Co. | QURE Stock News - GuruFocus
uniQure (NASDAQ:QURE) Given "Buy" Rating at HC Wainwright - MarketBeat
Uniqure stock soars 196% after breakthrough Huntington’s disease drug results - The Economic Times
uniQure (NASDAQ:QURE) Sets New 52-Week HighTime to Buy? - MarketBeat
uniQure (QURE) Shows Promising Results in Huntington's Disease S - GuruFocus
uniQure Announces Refinancing of Existing $50M Debt and Securing Up to an Additional $125M In Funding - citybiz
uniQure (QURE) Stock Jumps 150% on Breakthrough Huntington’s Disease Data - parameter.io
Transcript : UniQure N.V.Special Call - MarketScreener
uniQure Leaps on Huntington Test Results - Baystreet.ca
uniQure stock rating reiterated at Buy by Stifel on strong Huntington’s data - Investing.com India
uniQure (QURE) Sees Dramatic Pre-Market Surge Following Study Su - GuruFocus
Uniqure N V (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
2.51%
자본화:
|
볼륨(24시간):